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Abstract
Activation of the IRE1/XBP1s signaling arm of the unfolded protein response (UPR) is a 
promising strategy to correct defects in endoplasmic reticulum (ER) proteostasis implicated in 
diverse diseases. However, no pharmacologic activators of this pathway identified to date are 
suitable for ER proteostasis remodeling through selective activation of IRE1/XBP1s signaling. 
Here, we use high-throughput screening to identify non-toxic compounds that induce ER 
proteostasis remodeling through IRE1/XBP1s activation. We employ transcriptional profiling to 
stringently confirm that our prioritized compounds selectively activate IRE1/XBP1s signaling 
without activating other cellular stress-responsive signaling pathways. Furthermore, we 
demonstrate that our compounds improve ER proteostasis of destabilized variants of amyloid 
precursor protein (APP) through an IRE1-dependent mechanism and reduce APP-associated 
mitochondrial toxicity in cellular models. These results establish highly selective IRE1/XBP1s 
activating compounds that can be widely employed to define the functional importance of IRE1/
XBP1s activity for ER proteostasis regulation in the context of health and disease.
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INTRODUCTION
The unfolded protein response (UPR) is the primary signaling pathway activated by 
endoplasmic reticulum (ER) stress1, 2. The UPR comprises three signaling cascades 
activated downstream of the ER stress-sensing proteins IRE1, PERK, and ATF63, 4. In 
response to acute ER stress, UPR activation results in transcriptional and translational 
signaling to alleviate the misfolded protein load in the ER and promote adaptive remodeling 
of ER function and global cellular physiology5, 6. However, in response to chronic or severe 
ER insults, prolonged UPR signaling induces a pro-apoptotic response that results in cellular 
death7, 8. Through this combination of adaptive and pro-apoptotic signaling, the UPR 
dictates cellular function and survival in response to diverse pathologic insults.
The capacity of UPR signaling pathways to promote adaptive remodeling makes them 
attractive targets to ameliorate imbalances in ER proteostasis associated with etiologically 
diverse diseases9–11. The IRE1 pathway is the most evolutionarily conserved arm of the 
unfolded protein response (UPR), as it is found in all eukaryotes from yeast to mammals12. 
In response to ER stress, IRE1 is activated through a mechanism involving 
autophosphorylation, oligomerization, and allosteric activation of a cytosolic 
endoribonuclease (RNAse) domain 13–15. This RNAse is involved in splicing the XBP1 
mRNA, resulting in a frameshift that allows translation of the active XBP1 spliced (XBP1s) 
transcription factor 13, 16. XBP1s adapts ER proteostasis through the increased expression of 
stress-responsive genes including chaperones and degradation factors5, 6. The activated IRE1 
RNAse domain also promotes the degradation of ER-localized mRNAs through a process 
known as regulated IRE1-dependent decay (RIDD)17, 18. While the functional implications 
of RIDD remain to be fully established, recent results suggest that RIDD plays a protective 
role during ER stress through the selective degradation of mRNA encoding pro-apoptotic 
factors (e.g., DR5) and increased microautophagy through the degradation of BLOS117, 19. 
Thus, IRE1 activation can promote adaptive remodeling that alleviates ER stress and 
enhances ER proteostasis through XBP1 splicing and/or RIDD.
Increasing IRE1/XBP1s activity offers a unique opportunity to ameliorate pathologic 
imbalances in ER proteostasis implicated in diverse diseases. XBP1s overexpression 
promotes neuroprotection in animal models of neurodegenerative disease including 
Parkinson’s disease, Huntington’s disease, and peripheral nerve injury20–22. Increasing 
XBP1s can also promote the degradation of destabilized amyloid precursor protein (APP) 
mutants, reducing extracellular populations of the APP cleavage product Aβ associated with 
Alzheimer’s disease (AD)23, 24. Furthermore, chemical genetic activation of IRE1/XBP1s 
reduces the intracellular aggregation of destabilized, aggregation-prone variants of 
rhodopsin and α1-antitrypsin (A1AT) implicated in retinitis pigmentosa and A1AT 
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deficiency, respectively5, 25, 26. IRE1/XBP1s activation is also advantageous in models of 
other disorders including diabetes and myocardial infarction27, 28.
Based on the above, there is significant interest in identifying non-toxic compounds that 
activate IRE1/XBP1s signaling. Previous work identified compounds that allosterically 
activate the IRE1 RNAse by binding the IRE1 kinase active site13–15. While these 
compounds are useful for defining the mechanism of IRE1 activation, many show off-
pathway activity and/or toxicity, limiting their utility for defining the functional implications 
of IRE1/XBP1s activation in health and disease15, 29, 30. This necessitates the development 
of new compounds that activate IRE1/XBP1s through an alternative mechanism.
Here, we use a high-throughput screening (HTS) approach to identify non-toxic compounds 
that activate IRE1-dependent XBP1 splicing through a mechanism independent of binding 
the IRE1 kinase active site. We utilize RNAseq transcriptional profiling to demonstrate the 
selectivity of these compounds for IRE1/XBP1s signaling over other arms of the UPR or 
other stress-responsive signaling pathways. These compounds, which are prioritized on the 
fidelity of their transcriptional response, offer an opportunity to promote adaptive ER 
proteostasis remodeling through selective IRE1/XBP1s activation. To exemplify this, we 
demonstrate that our compounds promote the degradation of AD-associated APP mutants 
through an IRE1-dependent mechanism and mitigate APP-associated mitochondrial toxicity 
in cell models. Our results establish IRE1/XBP1s activating compounds that provide new 
opportunities to explore the mechanisms by which signaling through this pathway influences 
cellular physiology, and to define the utility of IRE1/XBP1s signaling for ameliorating 
pathologies associated with etiologically diverse diseases.
RESULTS
HTS to Identify IRE1/XBP1s Activating Compounds
We utilized a HEK293TREX cell line stably expressing a XBP1-Renilla luciferase (XBP1-
RLuc) splicing reporter to identify compounds that activated the IRE1/XBP1s signaling 
pathway (Fig. 1A, Extended Data Fig. 1A)31, 32. Activated IRE1 splices mRNA encoded by 
this reporter, resulting in a frame-shift that allows RLuc expression31. We confirmed that the 
XBP1-Rluc reporter is activated by the ER stressor thapsigargin (Tg; a SERCA inhibitor) 
and is blocked by co-treatment with the selective IRE1 RNAse active site inhibitor 4μ8c33 
(Extended Data Fig. 1B). We miniaturized this assay to a 1536-well plate format and 
screened the 646,251 compound Scripps Drug Discovery Library at the Scripps Research 
Institute Molecular Screening Center (SRIMSC)(Fig. 1A and Supplementary Table 1). Our 
primary screen identified 10,114 compounds that activated XBP1-RLuc activity >13.83% 
relative to Tg (Extended Data Fig. 1C). We removed compounds previously found to activate 
cell-based reporters of the cytosolic heat shock response34, as well as promiscuous 
compounds identified as positive hits in >7 assays at the SRIMSC (Fig. 1A, Extended Data 
Fig. 1D,E). We then selected the top ~6,400 compounds for triplicate confirmation and 
toxicity screening. Compounds (5.17 μM) that reduced cell viability >26.19% were removed 
(Extended Data Fig. 1F). We then deprioritized compounds which also activated other UPR 
signaling arms by removing compounds previously reported to activate the ATF6-selective 
ERSE-luciferase reporter31 (Fig. 1A and Extended Data Fig. 1D,G). From these data, we 
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selected 638 compounds that preferentially activate the XBP1-RLuc reporter for further 
characterization (Source Data Table 1).
We removed compounds that showed an EC50 for XBP1-Rluc activation >3 μM, in dose 
response studies, and maximal activity <20% relative to Tg activation (Extended Data Fig. 
1H). We then performed iterative chemical subclustering of these hits to yield a 
representative set of 128 compounds that reflects the diversity and relative abundance of 
similar scaffolds among these top hits (Fig. 1B, Supplementary Table 2). The two most 
represented groups in this analysis were Cluster “H” containing an aryl sulfonamide moiety 
and Cluster “A” containing a N1-phenyl substituted pyrazolopyrimidine substructure (Fig. 
1B, outlined in red). These structures are commonly found in compounds that bind kinase 
active sites, suggesting they likely activate IRE1 by binding the IRE1 kinase domain35. 
Since we were focused on identifying compounds that activate IRE1 independent of this 
mechanism, we excluded compounds in Clusters A and H in the initial characterization. 
Instead, we selected 7 compounds that represent 5 different structural classes for immediate 
follow-up (Fig. 1C, Supplementary Table 3).
Compounds Promote IRE1-Dependent XBP1 Splicing
We confirmed concentration-dependent activation of XBP1-RLuc in HEK293TREX cells, 
demonstrating reporter activation to levels 35-50% that observed with Tg and EC50’s 
consistent with those observed during HTS (Fig. 2A, Extended Data Fig. 2A, and 
Supplementary Table 2). Importantly, we confirmed that co-administration of our 
compounds with the IRE1 RNAse active site inhibitor 4μ8c blocked compound-dependent 
activation of XBP1-RLuc (Fig. 2A). Next, we showed that our compounds activate the IRE1/
XBP1s-selective target gene DNAJB9 (ERDJ4; Fig. 2B, Extended Data Fig. 2B) to levels 
30–50% those observed for Tg (Fig. 2B), mirroring the levels of activation observed in our 
reporter assay (Fig. 2A). Compound-dependent DNAJB9 expression was inhibited in cells 
co-treated with the IRE1 RNAse active site inhibitor 4μ8c, confirming that this effect is 
IRE1 dependent (Fig. 2B). Importantly, our compounds did not significantly induce the 
PERK-regulated target gene CHOP or the ATF6-regulated target gene BiP (HSPA5), 
indicating that our compounds are selective for the IRE1/XBP1s arm of the UPR (Extended 
Data Fig. 2C–F) Collectively, these results suggest that our compounds selectively activate 
IRE1/XBP1s signaling independent of other UPR signaling pathways.
We selected compounds IXA1 (1), IXA4 (4), and IXA6 (6) (Fig. 1C) as our top hits based 
on their selective IRE1-depedendent induction of DNAJB9, their EC50 of XBP1-RLuc 
activation of <3 μM, and their maximal activation of IRE1/XBP1s signaling to levels 
~40-50% that observed with Tg. We confirmed that IXA1, IXA4, and IXA6 moderately 
increased IRE1-dependent Xbp1 splicing in wild-type mouse embryonic fibroblast (MEF) 
cells, but not in Ire1-deficient MEF cells, further demonstrating that these compounds 
increase Xbp1 splicing through an IRE1-dependent mechanism (Extended Data Fig. 2G).
Compound Activity Requires IRE1 Phosphorylation
Compounds that activate the IRE1 RNAse through binding the IRE1 kinase domain inhibit 
IRE1 autophosphorylation and can elicit off-target activity likely associated with binding to 
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other kinases15, 29, 30. Thus, we sought to define the impact of IXA1, IXA4, and IXA6 on 
IRE1 kinase activity. Treatment with APY29, an IRE1 kinase inhibitor that allosterically 
activates the IRE1 RNAse15, blocked Tg-dependent IRE1 phosphorylation in HEK293T 
cells measured by a band shift in Phos-tag gel electrophoresis (Fig. 2C). In contrast, all three 
of our prioritized compounds increased IRE1 phosphorylation in these cells, indicating that 
they promote IRE1 autophosphorylation in the presence or absence of ER stress. 
Furthermore, co-treatment of IXA1, IXA4, and IXA6 with the IRE1 kinase inhibitor 
KIRA6, a compound that binds the IRE1 nucleotide binding pocket and inhibits both IRE1 
kinase and RNAse activity30, inhibits IRE1-dependent XBP1 splicing in HEK293T cells 
(Fig. 2D). Similarly, our compounds did not significantly increase XBP1s mRNA levels in 
Ire1-deficient MEF cells reconstituted with the kinase inactive P830L IRE1 (Fig. 2E). 
Collectively, these results indicate that our compounds do not bind the IRE1 kinase active 
site, but instead activate IRE1/XBP1s signaling through a mechanism requiring IRE1 
autophosphorylation.
IXA4 and IXA6 Selectively Activate IRE1/XBP1s Signaling
We next performed RNAseq to define the selectivity of our compounds for IRE1/XBP1s 
signaling (Source Data Table 2). The majority of genes induced by IXA1, IXA4, and IXA6 
are known transcriptional targets of IRE1/XBP1s (Fig. 3A–C). These include the ER 
proteostasis factors SEC24D, DNAJB9, and HERPUD15. We next defined the selectivity of 
our compounds for IRE1/XBP1s signaling relative to other arms of the UPR. We assessed 
selectivity by monitoring the expression of genesets comprised of 10–20 genes that are 
preferentially induced by the IRE1/XBP1s, ATF6, or PERK UPR signaling pathways 
(Source Data Table 3)5, 36. For this analysis, we normalized the expression of individual 
genes to that observed in Tg-treated cells (Tg representing 100% activation of each gene). 
This allows us to directly compare gene expression without complications arising from 
differential expression36. We found that IXA1, IXA4, and IXA6 activate the IRE1/XBP1s 
geneset to levels ~30–40% that observed for Tg (Fig. 3D–F); levels nearly identical to those 
observed in other experiments (Fig. 2A,B). Our compounds showed only a modest increase 
in the activation of the ATF6 target geneset (<20% that observed with Tg), which is 
consistent with previous reports showing overlap between genes primarily regulated by 
ATF6 and their mild induction by IRE1/XBP1s (e.g., BiP; Extended Data Fig. 2F)5. Thus, 
these results indicate that our compounds do not significantly activate ATF6 transcriptional 
signaling. However, IXA1 did increase expression of the PERK geneset, indicating mild 
activation of the PERK pathway (Fig. 3D). Notably, IXA4 and IXA6 did not activate the 
PERK geneset (Fig. 3E,F). Collectively, these results indicate that compounds IXA4 and 
IXA6 preferentially activate IRE1/XBP1s signaling, while compound IXA1 shows some 
promiscuous activity in the context of UPR signaling.
We additionally evaluated IRE1 RIDD activity using our RNAseq dataset. Despite observing 
robust IRE1/XBP1s transcriptional activity following 4 hrs of treatment, we did not observe 
significant reductions in the RIDD targets SCARA3, BLOC1S1 or COL6A117, although the 
levels of these mRNA are reduced in Tg-treated cells (Extended Data Fig. 3A–C). This may 
reflect a dependence of RIDD on PERK-dependent eIF2α phosphorylation.37 Taken 
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together, these results indicate that our prioritized compounds promote adaptive IRE1/
XBP1s signaling, but not RIDD, following 4 hrs of treatment in HEK293T cells.
Compounds Activate the XBP1s Transcriptional Response
Gene Ontology (GO) analysis shows that our IRE1/XBP1s activating compounds primarily 
induce expression of genes annotated with GO terms related to ER stress and the UPR (Fig. 
4A–B, Extended Data 4A, Supplementary Table 4). This suggests that our compounds do 
not activate other stress-signaling pathways. Consistent with this, applying a geneset 
approach similar to that described in Fig. 3D–F36, we show that our compounds do not 
significantly activate stress-responsive proteostasis pathways such as the cytosolic heat 
shock response, the oxidative stress response, the mitochondrial unfolded protein response, 
or the NFB inflammatory response (Extended Data Fig. 4B–D, Source Data Table 3). These 
results indicate that IXA4 and IXA6 (and to a lesser extent IXA1) do not significantly 
activate other stress responsive signaling pathways apart from IRE1/XBP1s.
Next, we compared the expression of the top 100 genes significantly induced by our 
compounds to the expression of these genes following stress-independent XBP1s or ATF6 
transcription factor activation in HEK293DAX cells, where chemical genetic activation of 
XBP1s or ATF6 transcriptional signaling can be achieved by addition of different activating 
ligands5. Interestingly, the majority of the top 100 genes induced by IXA4 and IXA6 
overlapped with genes induced by genetic XBP1s activation (Extended Data Fig. 5A,B), 
although, as expected, genetic XBP1s activation induces these genes to higher extents 
(Extended Data Fig. 4E). However, substantial overlap with ATF6 target genes was not 
observed, further indicating that our compounds do not significantly activate this UPR 
pathway (Extended Data Fig. 5A,B). The high level of overlap observed for genes induced 
by XBP1s and our compounds is further evident when comparing the groups of genes 
induced >1.2 fold by either IXA4 or IXA6 and genetic XBP1s activation. Compound IXA4 
shows 88% overlap of genes induced >1.2 fold, while compound IXA6 shows 64% overlap 
(Fig. 4C,D). In contrast, compound IXA1 shows less overlap with genetic XBP1s activation 
(Extended Data Fig. 4F,5C), reflecting the more promiscuous nature of this compound (Fig. 
3D). Interestingly, of the 10 non-overlapping genes identified for IXA4 (Fig. 4C), 9 are also 
induced by IXA6, likely reflecting a similar mechanism of induction (Extended Data Fig. 
4G). Two of these genes, IDI1 and SLC35A3 are reported to be regulated by IRE1/
XBP1s38, 39. Furthermore, the mild IXA4-dependent increase in LRRCC1 appears to be 
reduced by co-treatment with 4μ8c, suggesting that this gene is also regulated by IRE1 
(Extended Data Fig. 4H). In contrast, HSPA1A and HSPA1B are induced by many different 
stress pathway activators through an undefined mechanism36 and the mild IXA4-dependent 
increase in CETN3 does not appear sensitive to 4μ8c (Extended Data Fig. 4I). This indicates 
that IXA4 may induce a small subset of genes through an IRE1-independent mechanism. 
Taken together, the results in Fig. 4 confirm that IXA4 is the most selective for the IRE1/
XBP1s signaling pathway. Thus, we prioritized IXA4 for further mechanistic scrutiny and 
phenotypic studies based on the fidelity of its transcriptional response.
We confirmed the identity and chemical purity of IXA4 using NMR and HPLC 
(Supplementary Figure 1). We then used immunoblotting to show that IXA4 increases 
Grandjean et al. Page 6













XBP1s protein in HEK293T cells to levels ~40% that with Tg, but did not significantly 
increase phosphorylation of PERK or eIF2, further highlighting the selectivity of this 
compound (Extended Data Fig. 6A). Similarly, we showed IXA4 selectively upregulates 
XBP1s mRNA, relative to genes regulated by ATF6 (e.g., BiP) or PERK (e.g., CHOP), in 
other cell lines including Huh7 and SHSY5Y cells (Extended Data Fig. 6B,C). Similar 
results were observed for IXA6 (Extended Data Fig. 6A–C). Lastly, phosphokinase profiling 
shows that IXA4 did not increase phosphorylation of JNK or c-Jun (Extended Data Fig. 6D) 
– two kinase targets phosphorylated upon chronic IRE1 activation through an XBP1s-
independent mechanism40. Other kinase targets measured in this assay were also not 
significantly impacted by IXA4 treatment. These data further support the selective activation 
of IRE1/XBP1s UPR signaling pathway afforded by IXA4.
IXA4 Reduces Secretion of APP through IRE1 activation
IRE1/XBP1s signaling promotes targeted remodeling of ER proteostasis pathways 
comprised of chaperones, folding enzymes, trafficking proteins, and degradation factors5, 6. 
Consistent with its selectivity for IRE1/XBP1s, IXA4 also promotes selective transcriptional 
remodeling of ER proteostasis pathways, relative to cytosolic or mitochondrial pathways 
(Fig. 5A, Source Data Table 2,3). Quantitative immunoblotting of the IRE1/XBP1s 
trafficking factor SEC24D confirmed IXA4-dependent increases in ER proteostasis factor 
gene expression correspond to increased protein levels (Extended Data Fig. 7A). Similar 
results were observed with IXA6 (Extended Data Fig. 7A,B).
The potential of our compounds to remodel the ER proteostasis network through IRE1/
XBP1s activation suggests that these compounds could correct pathologic imbalances in ER 
proteostasis for disease-relevant proteins such as amyloid precursor protein (APP). APP is a 
secretory protein that undergoes proteolytic processing to produce aggregation-prone 
cleavage products including the amyloidogenic peptide Aβ41. Enhancing ER proteostasis 
through XBP1s overexpression reduces secretion of toxic Aβ23, 24. Thus, we predicted that 
the enhanced ER proteostasis environment afforded by IRE1/XBP1s activation by our 
compounds would similarly reduce Aβ secretion.
We show that IXA4 reduced Aβ levels 50% in conditioned media prepared on CHO7PA2 
cells expressing the V717F APP (APPV717F) mutant (Fig. 5B)42. We confirmed compound-
dependent IRE1/XBP1s activation in these cells by qPCR (Extended Data Fig. 7C). 
Importantly, IXA4 did not significantly influence CHO7PA2 viability measured by CellTiter 
Glo (Extended Data Fig. 7D). Similarly, we did not observe reductions in cell proliferation 
or increases in PARP cleavage in IXA4-treated CHO7PA2 cells (Extended Data Fig. 7E,F). 
These results indicate that the compound-dependent reduction in Aβ secretion cannot be 
attributed to cell death. Importantly, the IXA4-dependent reduction in Aβ secretion is 
blocked by co-treatment with 4μ8c, confirming this reduction is dependent on IRE1 RNAse 
activity (Fig. 5B). Similar results were observed in CHO7WD10 cells stably expressing wild-
type APP (APPWT) and in cells treated with the alternative IRE1/XBP1s activator IXA6 
(Extended Data Fig. 7D–H).
XBP1s overexpression has been shown to reduce Aβ secretion through the increased 
targeting of APP to ER-associated degradation (ERAD).23, 24 Interestingly, IXA4 reduced 
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APPV717F protein levels in both lysates and conditioned media prepared on CHO7PA2 cells, 
indicating that this compound increases APP degradation (Fig. 5C, Extended Data Fig. 8A). 
This reduction was reversed by co-treatment with either 4μ8c or the proteasome inhibitor 
MG132 (Fig. 5C, Extended Data Fig. 8A–C), indicating that APPV717F levels were reduced 
through a mechanism involving both IRE1 RNAse activity and ERAD via the proteasome. 
This is consistent with reports demonstrating that XBP1s overexpression increases APP 
ERAD.24 We further demonstrated that IXA4 reduces APPV717F secretion and increases 
APPV717F degradation using [35S] metabolic labeling (Fig. 5D–F). Similar results were 
observed with IXA6 (Extended Data Fig. 8D). Collectively, these results demonstrate that 
our compounds reduce Aβ secretion and increase APP degradation through an IRE1-
dependent mechanism.
IXA4 prevents APP-associated mitochondrial dysfunction
Previous results show that overexpression of wild-type (APPWT) or Swedish APP (APPSW) 
double mutant (K595N/M596L) induces mitochondrial dysfunction in SHSY5Y cells 
through the production of toxic APP cleavage products that localize to mitochondria and 
mitochondria-associated ER membranes (MAMs)43, 44. Consistent with this, overexpression 
of APPWT or APPSW in SHSY5Y resulted in a 25% or 40% reduction of mitochondrial 
membrane potential, respectively, as measured by tetramethylrhodamine (TMRE) staining 
(Fig. 6A,B). Overexpression of APPSW in SHSY5Y cells modestly increased expression of 
the IRE1/XBP1s target gene DNAJB9, but not other UPR genes such as the PERK-regulated 
target gene CHOP (Extended Data Fig. 9A,B). Treatment with IXA4 further increased 
DNAJB9 expression, indicating that our compounds are active in this model. Interestingly, 
treatment with IXA4 prevented the APPWT- or APPSW-dependent reductions in 
mitochondrial membrane potential in these cells (Fig. 6C,D and Extended Data Fig. 9C). 
This indicates that pharmacologically enhancing IRE1/XBP1s activity can block APP-
associated mitochondrial depolarization.
Mitochondrial depolarization decreases the capacity for cells to produce ATP through 
oxidative phosphorylation at the inner mitochondrial membrane. Thus, APPSW-dependent 
mitochondrial depolarization should reduce mitochondrial ATP production. To confirm this, 
we demonstrated that APPSW overexpression reduced ATP levels in SHSY5Y cells cultured 
in galactose-containing media, where ATP is primarily produced by mitochondria, but not in 
SHSY5Y cells cultured in glucose media, where ATP is primarily produced by glycolysis 
(Fig. 6E)45. Importantly, treatment with IXA4 rescued ATP levels in APPSW-overexpressing 
cells cultured in galactose media, further demonstrating that this compound mitigates 
mitochondrial dysfunction induced by toxic APPSW overexpression (Fig. 6F).
DISCUSSION
IRE1 activating compounds have traditionally been developed by targeting the IRE1 
nucleotide binding pocket to induce allosteric activation of the IRE1 RNAse13–15. While 
these types of compounds have provided important insights into the molecular mechanism of 
IRE1 activation, their utility for defining the functional implications of IRE1/XBP1s 
signaling is limited due to off-pathway activity, likely due to their binding to other 
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kinases15, 29, 30. This indicates that new strategies are required to establish highly selective 
IRE1/XBP1s activating compounds that can be used to probe the biological and potentially 
therapeutic benefit of IRE1/XBP1s signaling in the context of diverse diseases. The 
implications of finding these highly selective IRE1/XBP1s activators is evident from recent 
work establishing non-toxic, selective activators of the ATF6 UPR signaling pathway, which 
have revealed new insights into the functional importance of ATF6 activity in diverse 
biological functions including ER proteostasis remodeling, mammalian development, and 
cardiac protection against myocardial infarction31, 46, 47.
Here, we employ a screening strategy that prioritizes transcriptional profiling over 
mechanism-based activation to identify non-toxic compounds that selectively activate the 
IRE1/XBP1s arm of the UPR. Our compounds (e.g., IXA4) activate IRE1/XBP1s signaling 
without globally activating the UPR or other stress-responsive signaling pathways (e.g., the 
heat shock response or oxidative stress response). Importantly, our compounds increase 
IRE1 RNase activity through a mechanism independent of binding the IRE1 nucleotide-
binding pocket. This demonstrates that our compounds are distinct from currently available 
IRE1 activators, which bind the kinase active site. Interestingly, we showed that treatment of 
HEK293T cells with our prioritized compound IXA4 does not induce XBP1s-independent 
IRE1 signaling such as RIDD or JNK phosphorylation – two aspects of IRE1 activity often 
associated with chronic activation of this signaling pathway37, 40. The lack of RIDD and 
JNK phosphorylation could reflect the moderate activation of IRE1/XBP1s signaling 
afforded by our compounds or requirements of other signaling inputs (e.g., PERK 
activation37) to promote their activation. However, it is possible that our compounds could 
activate these aspects of IRE1 signaling in other cell types or experimental conditions, 
although this could likely be controlled through varying the compound dosage and 
administration.
While the mechanism by which our compounds activate IRE1/XBP1s signaling requires 
further exploration, we show that they induce adaptive ER proteostasis remodeling that 
mimics that observed with chemical genetic XBP1s activation. This provides new 
opportunities to define the functional implications of IRE1/XBP1s signaling in the context 
of health and disease. We demonstrate this potential by showing that our prioritized 
compound IXA4 improves ER proteostasis of AD-relevant APP mutants, reducing the 
secretion of Aβ through the increased targeting of APP to degradation. Further, we show that 
IXA4 reduces mitochondrial dysfunction associated with mutant APP overexpression, likely 
reflecting the reduced intracellular APP afforded by compound treatment. These results 
highlight the potential for targeting ER proteostasis to mitigate pathologic disruption in other 
organelles, including the mitochondria, which can be induced by destabilized, disease-
associated proteins.
Genetic activation of IRE1/XBP1s signaling promotes protection against different types of 
pathologic insults associated with multiple diseases20–22, 25, 28, 48. This indicates that IRE1 
represents a potential therapeutic target for these disorders. However, in the context of ER 
stress, chronic IRE1 activity can promote detrimental phenotypes such as increased 
apoptosis and inflammation in models of diseases such as atheroscleorosis and sepsis49, 50, 
potentially limiting the therapeutic applications for IRE1/XBP1s activating compounds. 
Grandjean et al. Page 9













Pharmacologic IRE1/XBP1s activation afforded by our compounds (e.g., IXA4) offers 
advantages over genetic strategies to probe the therapeutic potential for IRE1/XBP1s 
activation to intervene in these diseases. Our compounds allow selective activation of IRE1/
XBP1s in disease-relevant models, independent of genetic manipulation. Furthermore, they 
allow dosable and temporal control over IRE1/XBP1s activity using different dosing 
regimens, potentially limiting the adverse outcomes associated with chronic IRE1 activation. 
Thus, the highly selective, non-toxic IRE1/XBP1s activating compounds established herein 
(e.g., IXA4) provide new opportunities to probe the functional implications of this signaling 
pathway in diverse contexts and define the therapeutic potential for activating IRE1 to 
mitigate pathologic imbalances in cellular physiology implicated in diverse diseases.
ONLINE METHODS
Materials and Reagents
Antibodies: APP (6E10, Fisher Scientific Cat #501029533), APP (HRP-4G8, Fisher 
Scientific Cat #501029498), SEC24D (mouse) antibody was provided as a generous gift 
from the Balch Lab at TSRI, XBP1s (Cell Signaling Cat #12782S), KDEL (Enzo Cat # ADI-
SPA-827-F), P-eIF2α (Cell Signaling Cat #9721S), Tot-eIF2α (Abcam Cat # ab5369), 
PERK (Cell Signaling Cat #3192S), PARP (Cell Signaling Cat #9542S), Tubulin (Sigma Cat 
# T6074-200UL)
Pharmacologics: Thapsigargin (Fisher Scientific Cat # 50-464-295), 4μ8c (EMD Millipore 
Cat #412512), IXA1 (ChemDiv Cat # C522-3739), IXA2 (ChemDiv Cat # C527-0672), 
IXA3 (Hit2Lead Cat # SC-46317020), IXA4 (Hit2Lead Cat # SC-91093541), IXA5 (Life 
Chemicals Cat # F3164-0105), IXA6 (Life Chemicals Cat # F5120-0005), IXA7 (Life 
Chemicals Cat # F5098-0023), KIRA6 (Selleck Chemicals Cat #S8658), Staurosporine 
(LKT Cat # S7600-1 mg), MG132 ( Selleck Chem Cat# S3619)
High Throughput Screening (including all the filtering steps and the Chemical Clustering)
HEK293TREX cells incorporating either the XBP1-Rluc or ERSE-FLuc reporters were 
collected by trypsinization and resuspended at a density of 500,000 cells per mL. The assay 
was started by dispensing 5 μL of cell suspension into each well of white, solid-bottom 
1536-well plates using a flying reagent dispenser (FRD) and placed into an online incubator 
for 3 hrs. Cells were then treated with 34 nL/well of either test compounds to give final 
concentrations of 5.17 μM, DMSO (low control, final concentration 0.68%, 0% activation) 
or 37 μM of Delta-7 thapsigargin (high control, final concentration 500 nM, 100% 
activation). Plates were incubated for 18 hrs at 37°C, removed from the incubator and 
equilibrated to room temperature for 10 min. Luciferase activity was detected by addition of 
5 μL of Renilla-Glo reagent (Promega) to each well. After a 10 min incubation time, light 
emission was measured with the ViewLux reader (PerkinElmer). Tg exhibited a robust 
signal to noise ratio (4.06 +/− 0.23) and was used to confirm consistent assay performance 
across experimental plates (Z’ = 0.69 +/− 0.01). Compound (5.17 μM) dependent XBP1-
RLuc activation was additionally normalized to Tg (assigned to be 100% activation) to allow 
comparisons between compounds across screening plates. The percent activation of each test 
compound was calculated as follows: % Activation = 100*(Test Compound- Median Low 
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Control) / (Median High Control – Median Low Control). Primary screening of the 646,275 
compound library at Scripps Florida yielded 10,114 hits for XBP1-Rluc activity at ≥ 13.83% 
activation by thapsigargin (three times the standard deviation of the negative DMSO control 
in the assay), an approximate 1.5% hit rate. Compounds that hit in more than 7 screens 
(promiscuity score) were eliminated, as well as those that elicited HSP70 activation. The top 
6,391 remaining compounds were moved forward to triplicate confirmation screening and 
HEK293TREX CTG cytotoxicity counterscreening. Toxic compounds found to reduce cell 
viability >26.19% (5.17 μM) relative to doxorubicin were removed, leaving 6,185 non-toxic 
compounds showing reproducible XBP1-RLuc activation. Duplicates were removed from 
the resulting list, and the top 638 activating compounds were moved forward for triplicate 
titration screening and HEK293TREX CTG titration counterscreening. These 638 compounds 
were subjected to hierarchical clustering using the Library MCS application from the 
ChemAxon JChem Suite, grouping 551 of these by 20 conserved structural motifs, with 87 
singletons. All 638 compounds were also subject to quality control measurements by LC-
MS, UV-vis spectroscopy, MS, and ELSD to confirm purity and mass. Those that did not 
pass both of these quality checks were eliminated. From titration data of the remaining 
compounds, those with < 20% reporter activation, and EC50s >3uM were eliminated. 
Additionally, compounds from the HEK293TREX CTG counterscreen with EC50s <3uM 
were also eliminated. Remaining clustered compounds were iteratively subclustered so that 
the diversity of the cluster would be captured by a smaller representative group, comprised 
only of compounds that activated the reporter to a practical degree for in vitro measurements 
(>30%). Remaining singleton compounds that passed quality control and showed reporter 
activation >30% were also included for in vitro assays.
RNASeq analysis (including Geneset analysis and GO-term analysis)
Cells were lysed and total RNA collected using the RNeasy mini kit, according to 
manufacturer’s instructions (Qiagen). Conventional RNAseq was conducted via BGI 
Americas on the BGI Proprietary platform, providing single-end 50bp reads at 20 million 
reads per sample. Alignment of sequencing data was done using DNAstar Lasergene 
SeqManPro to the GRCh37.p13 human genome reference assembly, and assembly data were 
imported into ArrayStar 12.2 with QSeq (DNAStar Inc.) to quantify the gene expression 
levels and normalization to reads per kilobase per million (RPKM). Differential expression 
analysis and statistical significance calculations between different conditions was assessed 
using “DESeq” in R, compared to vehicle-treated cells, using a standard negative binomial 
fit of the RPKM data to generate Fold Change quantifications.
Cell Culture and Transfections
Briefly, all cells lines were cultured in high-glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM; Corning-Cellgro) supplemented with 10% fetal bovine serum (FBS; Omega 
Scientific), 2 mM L-glutamine (Gibco), 100 U*mL−1 penicillin, and 100 μg*mL-1 
streptomycin (Gibco). SH-SY5Y cells in galactose conditions were cultured in glucose-free 
Dulbecco’s Modified Eagle’s Medium (DMEM; Corning-Cellgro) supplemented with 10% 
fetal bovine serum (FBS; Omega Scientific), 2 mM L-glutamine (Gibco), 100 U*mL−1 
penicillin, and 100 μg*mL-1 streptomycin (Gibco) and 5mM galactose. All cells were 
cultured under typical tissue culture conditions (37°C, 5% CO2). Cells were routinely tested 
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for mycoplasma every 6 months. No further authentication of cell lines was performed by 
the authors. Cells were transfected using calcium phosphate precipitation. All plasmids for 
transfection were prepared using the Qiagen Midiprep kit according to the manufacturers 
protocol. 7PA2 cells were kindly provided by Prof. E. Koo (University of California, San 
Diego).
qPCR, Transcriptional Profiling
Primers: hDNAJB9 (F: GGAAGGAGGAGCGCTAGGTC, R: 
ATCCTGCACCCTCCGACTAC)
hBiP (F:GCCTGTATTTCTAGACCTGCC, R: TTCATCTTGCCAGCCAGTTG)
hCHOP (F:ACCAAGGGAGAACCAGGAAACG, R: TCACCATTCGGTCAATCAGAGC)
hLRRCC1 (F:TCATCGAGAAAGAGAACAAGCGC, R: 
GATTATGACAGAGAAGCCACAGG)
hCETN3 (F:GATTATGACAGAGAAGCCACAGG, R: 
ATGCCTTGAGTATTTCTTCATGGG)
hRiboPro (F:CGTCGCCTCCTACCTGCT, R: CCATTCAGCTCACTGATAACCTTG)
mXBP1s (F:ACGAGGTTCCAGAGGTGGAG, R: TGTCCAGAATGCCCAAAAGG)
mRiboPro (F:TGTCATCGCTCAGGGTGTTG, R: AAGCCAAATCCCATGTCGTC)
hamXBP1u (F:CTCCAGAGACGGAGTCCAAG, R: 
CAGAGGTGCACGTAGTCTGAGTGCTG)
hamXBP1s (F:CTCCAGAGACGGAGTCCAAG, R: CACCTGCTGCGGACTC)
hamActin (F:AGCTGAGAGGGAAATTGTGCG, R: GCAACGGAACCGCTCATT)
The relative mRNA expression levels of target genes were measured using quantitative RT-
PCR. Cells were treated as described at 37°C, washed with Dulbecco’s phosphate-buffered 
saline (GIBCO), and then RNA was extracted using the RNeasy Mini Kit (QIAGEN). qPCR 
reactions were performed on cDNA prepared from 500 ng of total cellular RNA using the 
QuantiTect Reverse Transcription Kit (QIAGEN). The FastStart Universal SYBR Green 
Master Mix (Roche), cDNA, and primers purchased from Integrated DNA Technologies 
were used for amplifications (6 min at 95°C then 45 cycles of 10 s at 95°C, 30 s at 60°C) in 
an ABI 7900HT Fast Real Time PCR machine. Primer integrity was assessed by a thermal 
melt to confirm homogeneity and the absence of primer dimers. Transcripts were normalized 
to the housekeeping genes RiboPro and all measurements were performed in triplicate. Data 
were analyzed using the RQ Manager and DataAssist 2.0 softwares (ABI). qPCR data are 
reported as mean ± 95% confidence interval as calculated in DataAssist 2.0.
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Immunoblotting, SDS-PAGE, and Phos-tag SDS-PAGE
Cell lysates were prepared as previously described in RIPA buffer (50 mM Tris, pH 7.5, 150 
mM NaCl, 0.1 % SDS, 1% Triton X-100, 0.5% deoxycholate and protease inhibitor cocktail 
(Roche). Total protein concentration in cellular lysates was normalized using the Bio-Rad 
protein assay. Lysates were then denatured with 1X Laemmli buffer + 100 mM DTT and 
boiled before being separated by SDS-PAGE. Samples were transferred onto nitrocellulose 
membranes (Bio-Rad) for immunoblotting and blocked with 5% milk in Tris-buffered saline, 
0.5 % Tween-20 (TBST) following incubation overnight at 4°C with primary antibodies. 
Membranes were washed in TBST, incubated with IR-Dye conjugated secondary antibodies 
and analyzed using Odyssey Infrared Imaging System (LI-COR Biosciences). Quantification 
was carried out with LI-COR Image Studio software.
Phosphokinase Array
The Proteome Profile Human Phospho-kinase Array Kit from R&D Systems (Cat # 
ARY003C) was used to assess phosphorylation status of a panel of human kinases in 
HEK293T cells treated with IXA4 compared to vehicle. The array was performed per 
manufacturer instructions. Briefly, cell lysates were prepared after 4 hrs of treatment, and 
incubated on membranes containing antibodies for kinases of interest. Each antibody had 
been dotted in duplicate. After washing, HRP-conjugated secondary antibody cocktail was 
incubated on membranes. HRP substrate was then incubated on membranes, and dot blots 
were visualized via chemiluminescence with a Bio-Rad ChemiDoc XRS+.
PCR and Agarose Gel Electrophoresis
To amplify the spliced and unspliced XBP1 mRNA, XBP1 primers were used as described 
previously16. PCR products were electrophoresed on 2.5% agarose gel. GAPDH (forward 
5′GGATGATGTTCTGGAGAGCC3′, reverse 5′CATCACCATCTTCCAGGAGC3′) was 
used as a loading control. The size difference between the spliced and the unspliced XBP1 is 
26 nucleotides.
Aβ ELISA
7PA2 or 7WD10 cells were cultured on 96-well plates (Corning) and treated with IRE1 
activating compounds +/− 4μ8c overnight. The medium was then replaced with fresh 
medium containing treatment at a reduced volume (50%), culture medium was collected 
after 24 hrs. The medium was analyzed by an Aβ ELISA as follows. Monoclonal 6E10 anti-
Aβ(residues 1–17) mouse IgG1, (Biolegend) was coated in 50 mm carbonate buffer, pH 9.6, 
at 4°C overnight on high binding assay black plates (Costar), washed with TBST (tris 
buffered saline with 0.05% Tween 20) and blocked with 5% non-fat milk in TBST. Samples 
and standards (condition 7PA2 media) were incubated for 1.5 hrs, followed by addition of 
4G8 antibody [anti-Aβ residues 17–24, mouse IgG2b (Biolegend)] conjugated to 
horseradish peroxidase (HRP) and incubated for 1.5 hrs at 25°C. After washing, ABTS 
substrate was added, followed by detection with an absorbance plate reader.
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[35S] metabolic labeling experiments were performed as previously described5. Briefly, 
transfected CHO7PA2 cells were plated and treated on poly-D-lysine coated 6-well plates and 
metabolically labeled in DMEM-Cys/-Met (Corning CellGro, Mediatech Inc., Manassas, 
VA) supplemented with glutamine, penicillin/streptomycin, dialyzed fetal bovine serum, and 
EasyTag EXPRESS [35S] Protein Labeling Mix (Perkin Elmer) for 30 min. Cells were 
washed twice with complete media and incubated in pre-warmed DMEM for the indicated 
times. Media or lysates were harvested at the indicated times. Lysates were prepared in 
RIPA buffer (50mM Tris [pH 7.5], 150mM NaCl, 1% Triton X100, 0.5% sodium 
deoxycholate, 0.1% SDS) containing proteases inhibitors cocktail (Roche). APP species 
were immunopurified using protein G sepharose beads bound with 6E10 antibody and 
washed four times with RIPA buffer. The immunoisolates were then eluted by boiling in 6X 
Laemmli buffer and separated on 12% SDS-PAGE. Gels were stained with Coomassie Blue, 
dried, exposed to phosphorimager plates (GE Healthcare, Pittsburgh, PA) and imaged by 
autoradiography using a Typhoon Trio Imager (GE Healthcare). Band intensities were 
quantified by densitometry in ImageQuant. Fraction secreted was calculated using the 
equation: fraction secreted = [extracellular [35S]-APP signal at t / (extracellular [35S]-APP 
signal at t=0 + intracellular [35S]-APP signal at t=0)]. Fraction remaining was calculated 
using the equation: [(extracellular [35S]-APP signal at t + intracellular [35S]-APP signal at 
t) / (extracellular [35S]-APP signal at t=0 + intracellular [35S]-APP signal at t=0)].
CellTiterGlo Viability Assays
For determination of relative cellular ATP levels, SHSY5Y cells were seeded into flat black, 
poly-D-lysine coated 96-well plates (Corning). Cells were treated as indicated then lysed by 
the addition of CellTiter-Glo reagent (Promega). Samples were dark adapted for 10 min to 
stabilize signals. Luminescence was then measured in an Infinite F200 PRO plate reader 
(Tecan) and corrected for background signal. All measurements were performed in biologic 
triplicate.
TMRE Staining and Flow Cytometry
Cells were treated as indicated then incubated with TMRE dye (200 nM) for 30 mins at 
37°C. Samples were collected by trypsinization. Trypsin was neutralized by washing into 
cell culture media and then samples were washed twice in DPBS. Cell pellets were 
suspended into DPBS supplemented with 0.1% BSA. Fluorescence intensity of TMRE was 
recorded on the PE channel of a Novocyte Flow Cytometer (ACEA Biosciences, Inc). Data 
are presented as mean of the fluorescence intensity from 3 experiments. For each 
experiment, 10,000 cells per condition in triplicates were recorded.
DATA AVAILABILITY
The raw data that support the findings of this study are available within the paper and its 
Extended Data files (pertaining to Figures 1, 3, 4, and Extended Data Figures 1, 3, 4, and 5), 
and/or are available from the corresponding author upon reasonable request. The RNAseq 
data have been deposited to the public National Center for Biotechnology Information GEO 
repository under the data identifier GSE148802.
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Code for standard open-source DESeq differential gene expression RNAseq analysis used in 
R statistical software is available from the corresponding author upon reasonable request.
Extended Data
Extended Data Fig. 1. 
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A. Schematic of the XBP1-Renilla luciferase (XBP1-RLuc) splicing reporter used in our 
high-throughput screen to identify small molecule activators of IRE1/XBP1s signaling.
B. Graph showing XBP1-RLuc splicing reporter activation in HEK293TREX cells incubated 
with Tg (500 nM) in the presence or absence of 4μ8c (64 μM) for 16 hrs. Error bars show 
SD for n=3 replicates.
C. Plot showing XBP1-RLuc activation in HEK293TREX cells stably expressing the XBP1-
RLuc reporter treated with the 10,114 small molecules (6 μM; 18 hrs) identified as hits in 
the primary screen. Luminescence is shown as % signal relative to treatment with Tg (500 
nM; 18 hrs).
D. Venn diagram of overlap of compounds identified to activate the IRE1-dependent XBP1-
RLuc splicing reporter, the ATF6-selective ERSE-FLuc reporter, or the HSF1-dependent 
HSP70-FLuc reporter via high-throughput screening.
E. Plot showing XBP1-RLuc activation HEK293TREX cells (% signal compared to that 
observed with 500 nM Tg, 18 hrs) versus promiscuity score for our top 638 compounds 
identified by HTS. The promiscuity score reports on the number of assays performed at the 
TSRI-FL Screening Center where each compound was identified as a positive hit.
F. Plot showing IC50 for toxicity as measured by CellTiterGlo luminescence calculated from 
titration screening of 638 hit compounds. The dashed red lines indicates IC50 = 3 μM.
G. Plot showing IRE1-dependent XBP1-RLuc activation versus ATF6-selective ERSE-Fluc 
activation in HEK293TREX cells (% signal compared to that observed with 500nM Tg, 18 
hrs) for the subset of our top 638 compounds that were also identified to activate the ATF6-
selective ERSE-FLuc reporter. The dashed red line indicates equal XBP1s-Rluc and ERSE-
Fluc activation.
H. Plot showing XBP1-RLuc activation in HEK293TREX cells (% signal compared to that 
observed with 500nM Tg, 18 hrs) versus EC50 of XBP1-RLuc activation in HEK293TREX 
cells calculated from titration screening of hit 638 compounds. The dashed red lines 
indicates 20% Rluc activation and Rluc EC50 = 3μM.
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Extended Data Fig. 2. 
A. Plot showing XBP1-RLuc activation in HEK293TREX cells (% signal compared to that 
observed with 500nM Tg, 18 hrs) treated for 18 hrs with the indicated concentrations of 
prioritized IRE1/XBP1s activator. Error bars represent SD for n = 3 replicates.
B. Graph showing qPCR of the XBP1 target gene DNAJB9 in HEK293T cells treated for 4 
hrs with Tg (500 nM) in the presence or absence of 4μ8c (64 μM). Error bars show SE for 
n= 3. P-values were calculated using one-tailed Student’s t-test. **p<0.01.
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C. Graph showing qPCR of the ATF6 target gene BiP in HEK293T cells treated for 4 hrs 
with Tg (500 nM) in the presence or absence of 4μ8c (64 μM). Error bars show SE for n= 3. 
P-values were calculated using one-tailed Student’s t-test.
D. Graph showing qPCR of the PERK target gene CHOP in HEK293T cells treated for 4 hrs 
with Tg (500 nM) in the presence or absence of 4μ8c (64 μM). Error bars show SE for n= 3. 
P-values were calculated using one-tailed Student’s t-test.
E. Graph showing qPCR of the PERK target gene CHOP in HEK293T cells treated for 4 hrs 
with prioritized IRE1/XBP1s activators (10 μM) or Tg (500nM), in the presence or absence 
of 4μ8c (32 μM). Error bars show 95% CI for n= 3 replicates.
F. Graph showing qPCR analysis of the ATF6 target gene BiP in HEK293T cells treated for 
4 hrs with indicated compound (10 μM), or Tg (500nM), in the presence or absence of 4μ8c 
(32 μM). Error bars show 95% CI for n= 3 replicates.
G. cDNA gel showing splicing of XBP1 mRNA in WT MEF or Ire1−/− MEF cells treated 
with IXA1, IXA4, or IXA6 (10 μM) for 4 hrs.
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Extended Data Fig. 3. 
A. Graph showing log2 Fold change mRNA levels from RNAseq for the RIDD target 
SCARA3 in HEK293T cells treated with 10 μM IXA1, IXA4, IXA6, or 500 nM Tg for 4 
hrs. Error bars represent SD for n = 3 replicates.
B. Graph showing log2 Fold change mRNA levels from RNAseq for the RIDD target 
BLOC1S1 in HEK293T cells treated with 10 μM IXA1, IXA4, IXA6, or 500 nM Tg for 4 
hrs. Error bars represent SD for n = 3 replicates.
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C. Graph showing log2 Fold change mRNA levels from RNAseq for the RIDD target 
COL6A1 in HEK293T cells treated with 10μM IXA1, IXA4, IXA6, or 500nM Tg for 4 hrs. 
Error bars represent SD for n = 3 replicates.
Extended Data Fig. 4. 
A. Gene Ontology (GO) analysis of differentially expressed genes from RNAseq for 
HEK293T cells treated with IXA1 (10 μM, 4hrs). Top 15 entries with lowest FDR are 
shown. See Supplementary Table 4 for full GO analysis.
B. Graph showing fold change mRNA levels from RNAseq of target genes activated 
downstream of the UPR, HSR, OSR, and other stress signaling pathways in HEK293T cells 
treated with IXA1 (10 μM) for 4 hrs. The composition of these genesets is shown in Source 
Data Table 3. P-values were calculated using one-way ANOVA compared to “Other”. 
****p<0.0001.
C. Graph showing fold change mRNA levels from RNAseq of target genes activated 
downstream of the UPR, HSR, OSR, and other stress signaling pathways in HEK293T cells 
treated with IXA4 (10μM) for 4 hrs. The composition of these genesets is shown in Source 
Data Table 3. P-values were calculated using one-way ANOVA compared to “Other”. 
****p<0.0001.
D. Graph showing fold change mRNA levels from RNAseq of target genes activated 
downstream of the UPR, HSR, OSR, and other stress signaling pathways in HEK293T cells 
treated with IXA6 (10μM) for 4 hrs. The composition of these genesets is shown in Source 
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Data Table 3. P-values were calculated using one-way ANOVA compared to “Other”. 
****p<0.0001.
E. Bar graph showing fold change mRNA levels of the IRE1/XBP1s targets DNAJB9, 
SEC24D, and HSPA13 from RNAseq of HEK293DAX cells expressing dox-inducible XBP1s 
treated with dox (1 μg/mL) for 4 hr or HEK293T cells treated with compounds IXA1, IXA4, 
or IXA6 (10 μM) for 4 hrs.
F. Venn diagram of genes upregulated >1.2 fold (adjusted p-value <0.05) in HEK293T cells 
treated with compound IXA1 (10 μM) for 4 hrs in comparison to genes induced >1.2 fold 
(adjusted p-value < 0.05) in HEK293DAX cells treated with doxycycline (1 μg/mL) for 4 hrs. 
Genes listed in purple are top overlapping targets between conditions.
G. Graph showing log2Fold Change mRNA levels from RNAseq of the 10 non-overlapping 
genes activated in cells treated with IXA4 (10μM) compared to dox-inducible XBP1s. 
Log2Fold change mRNA levels of these genes in cells treated with IXA6 (10μM) are also 
included.
H. Graph showing qPCR of the LRRCC1 gene in 293T cells treated with IXA4 (10 μM) in 
the presence or absence of 4μ8c (64μM) for 4 hrs. Error bars show SE for n= 3.
I. Graph showing qPCR of the CETN3 gene in 293T cells treated with IXA4 (10 μM) in the 
presence or absence of 4μ8c (64μM) for 4 hrs. Error bars show SE for n= 3.
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Extended Data Fig. 5. 
A. Heat map of top 100 genes upregulated in HEK293T cells treated for 4 hrs with IXA4 (10 
μM) compared to dox-inducible XBP1s or TMP-stabilized DHFR.ATF6 in HEK293DAX 
cells treated with doxycycline (1 μg/mL) or TMP (10 μM) for 4 hr.
B. Heat map of top 100 genes upregulated in HEK293T cells treated for 4 hrs with IXA6 
(10μM) compared to dox-inducible XBP1s or TMP-stabilized DHFR.ATF6 in HEK293DAX 
cells treated with doxycycline (1 μg/mL) or TMP (10μM) for 4 hrs.
C. Heat map of top 100 genes upregulated in HEK293T cells treated for 4 hr with IXA1 (10 
μM) compared to dox-inducible XBP1s or TMP-stabilized DHFR.ATF6 in HEK293DAX 
cells treated with doxycycline (1 μg/mL) or TMP (10 μM) for 4 hrs.
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Extended Data Fig. 6. 
A. Representative immunoblots of XBP1s, PERK, eIF2α, and BiP in lysates prepared from 
HEK293T cells treated with vehicle, thapsigargin (1μM), IXA4 (10μM), or IXA6 (10 μM) 
for 4 hrs.
B. Graph showing qPCR of the XBP1 target gene DNAJB9, ATF6 target gene BiP, and 
PERK target gene CHOP in Huh-7 cells treated with IXA4 (10 μM) or IXA6 (10μM) in the 
presence or absence of 4μ8c (64μM) for 4 hrs. Error bars show SE for n=3 replicates. 
Statistics calculated from one-tailed Student’s t-test. *p<0.05, **p<0.01.
C. Graph showing qPCR of the XBP1 target gene DNAJB9, ATF6 target gene BiP, and 
PERK target gene CHOP in SHSY5Y cells treated with IXA4 (10 μM) or IXA6 (10μM) in 
the presence or absence of 4μ8c (64μM) for 4 hrs. Error bars show SE for n=4 replicates. 
Statistics calculated from one-tailed Student’s t-test. *p<0.05, **p<0.01.
D. Graph showing relative signal of phosphorylated target proteins by phosphokinase array 
dot immunoblotting in HEK293T cells treated with IXA4 (10μM) for 4 hrs. Error bars show 
SD for n=2.
Grandjean et al. Page 23













Extended Data Fig. 7. 
A. Representative immunoblots and quantification of SEC24D in lysates prepared from 
HEK293T cells treated with vehicle, IXA1, IXA4, or IXA6 (10 μM, 18 hrs). Error bars show 
SD for n= 3 replicates. P-values were calculated using one-tailed Student’s t-test. *p<0.05, 
**p<0.01.
B. Plot of log2 Fold Change mRNA levels from RNAseq in cells treated with IXA6 (10μM, 
4 hrs) of proteostasis factors found in the ER, cytosol/nucleus, or mitochondria. The 
composition of these proteostasis genesets is shown in Source Data Table 3.
C. Graph showing the Fold change mRNA ratio of Xbp1s:Xbp1u by qPCR in CHO7PA2 cells 
treated with IXA4 (10 μM) or thapsigargin (1μM) in the presence or absence of 4μ8c 
(64μM) for 4 hrs. Error bars show SE for n=3 replicates. Statistics calculated from one-tailed 
Student’s t-test. *p<0.05, **p<0.01.
D. Graph showing relative CellTiterGlo luminescence from CHO7PA2 cells treated with 
IRE1/XBP1s activators IXA4, or IXA6 (10 μM) in the presence or absence of 4μ8c (32 μM). 
Cells were treated for 18 hrs, media was then replaced and conditioned in the presence of 
treatments for 24 hrs before measuring ATP levels. Luminescence signal was normalized to 
that observed in untreated controls. Error bars represent SE for n = 3 replicates.
E. Graph showing cell counts (106cells/mL) of CHO7PA2 cells treated with IXA4 or IXA6 
(10 μM) in the presence or absence of 4μ8c (64 μM) for 24 hrs.
F. Immunoblot of mutant PARP in lysates collected from CHO7PA2 cells treated with IXA4 
or IXA6 (10 μM) or staurosporine (1 μM) for 24 hrs.
G. Graph showing relative signal from ELISA of secreted Aβ peptide from conditioned 
media prepared on CHO7WD10 cells treated with IXA4 or IXA6 (10 μM). Cells were 
pretreated for 18 hrs with compounds. Media was then replaced and conditioned in the 
presence of compounds for 24 hrs before harvesting the media for ELISA. Secreted Aβ was 
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normalized to that observed in untreated controls. Error bars represent SE for n = 3 
replicates.
H. Graph showing relative CellTiterGlo luminescence from CHO7WD10 cells treated with 
IRE1/XBP1s activators IXA4 or IXA6 (10 μM). Cells were treated for 18 hrs, media was 
then replaced and conditioned in the presence of treatments for 24 hrs before measuring ATP 
levels. Luminescence signal was normalized to that observed in untreated controls. Error 
bars represent SE for n = 3 replicates.
Extended Data Fig. 8. 
A. Representative immunoblot of mutant APP in media and lysates collected from CHO7PA2 
cells treated with IXA1 or IXA4 (10 μM) in the presence or absence of 4μ8c (64 μM). Cells 
were treated for 18 hrs, media was then replaced and conditioned in the presence of 
treatments for 24 hrs before harvesting.
B. Representative immunoblot of mutant APP in media and lysates collected from CHO7PA2 
cells treated with IXA4 or IXA6 (10 μM) in the presence or absence of MG132 (10 μM) for 
18hrs.
C. Quantification of immunoblots represented in panel B of relative APP signal in lysates or 
conditioned media from CHO7PA2 cells treated with IRE1/XBP1s activators IXA4 or IXA6 
(10 μM) in the presence or absence of MG132 (10 μM) for 18hrs. Error bars represent SE 
for n=4 replicates. Statistics calculated from one-tailed Student’s t-test. *p<0.05, **p<0.01, 
***p<0.001.
D. Representative autoradiogram showing the [35S] metabolic labeling of mutant APP in 
CHO7PA2 cells treated with IXA6 (10 μM) for 16 hrs prior to 30 min labeling. Media and 
lysates were collected at 0, 1, or 2 hrs and [35S]-labeled mutant APP was isolated by 
immunopurification. The experimental protocol is shown above. Fraction remaining was 
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calculated as described in Fig. 5D and fraction secretion was calculated as in Fig. 5E. Error 
bars represent SD for n = 3 replicates. P-values were calculated from one-tailed Student’s t-
test. *p<0.05.
Extended Data Fig. 9. 
A. Graph showing qPCR of the XBP1 target gene DNAJB9 in SHSY5Y cells transiently 
expressing empty vector (Mock) or Swedish mutant APP (APPSW) in the presence or 
absence of IXA4 (10 μM) for 72 hrs. Error bars show SE for n= 2. Statistics calculated from 
one-tailed Student’s t-test. *p<0.05, **p<0.01.
B. Graph showing qPCR of the PERK target gene CHOP in SHSY5Y cells transiently 
expressing empty vector (Mock) or APPSW in the presence or absence of IXA4 (10 μM) for 
72 hrs. Error bars show SE for n= 2.
C. Representative histograms showing TMRE staining of SHSY5Y cells transiently 
expressing empty vector (Mock) or wild-type APP (APPWT) in the presence or absence of 
IXA4 (10 μM) for 72 hrs.
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Figure 1. High-throughput screen to identify preferential IRE1/XBP1s activating compounds
A. Illustration of the screening pipeline employed to identify prioritized compounds that 
selectively activate the IRE1-dependent XBP1-RLuc reporter. This pipeline includes a 
primary screen to identify compounds that activate the XBP1-RLuc reporter, removal of 
compounds that activate reporters of other stress-responsive signaling pathways (e.g., the 
ATF6 arm of the UPR and the HSR), and structural clustering of selective activators into 
defined structural classes.
B. Network plot illustrating shared structural motifs among a subset of the 128 compounds 
identified to preferentially activate the XBP1-Rluc reporter >20%, display a maximal EC50 
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for reporter activation of <3 μM, and show an IC50 for toxicity of >3 μM. Prioritized 
compounds identified for subsequent studies are shown in red.
C. Chemical structures of our top 7 prioritized IRE1/XBP1s activators identified via high-
throughput screening.
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Figure 2. Compound-Dependent IRE1/XBP1s Activation Requires IRE1 Autophosphorylation
H. Luminescence in HEK293TREX cells stably expressing the XBP1-RLuc splicing reporter 
treated with indicated IRE1/XBP1s activators (10 μM) in the presence or absence of the 
IRE1 active site inhibitor 4μ8c (32 μM) for 18 hrs. Luminescence is shown as % signal 
relative to Tg (500 nM; 18 hr). Error bars represent SD for n = 3 replicates.
I. Graph showing qPCR of the XBP1 target gene DNAJB9 in HEK293T cells treated for 4 
hrs with the indicated compound (10 μM) or Tg (500 nM) in the presence or absence of 4μ8c 
(32 μM). Error bars show 95% CI for n = 3 replicates.
J. Immunoblot of IRE1 following Phos-tag SDS-PAGE to separate phosphorylated and 
unphosphorylated IRE1 in lysates prepared from HEK293T cells treated for 4 hrs with 10 
μM IXA1, IXA4, or IXA6 or 1 μM APY29 in the presence or absence of 500 nM Tg. 
Phosphorylated (p-IRE1) and unphosphorylated (IRE1) are indicated on the gel.
K. cDNA gel showing splicing of XBP1 mRNA in HEK293T cells treated for 4 hrs with 10 
μM IXA1, IXA4, IXA6, or 500 nM Tg in the presence or absence of 10 μM IRE1 kinase 
inhibitor KIRA6 for 4 hr.
L. Graph showing qPCR of Xbp1s mRNA in Ire1−/− MEFs reconstituted with WT or kinase 
inactive P830L IRE1, treated for 4 hrs with 10μM IXA1, IXA4, IXA6. Fold increase for 
each condition is presented relative to vehicle-treated control. Error bars represent SE for n = 
3 replicates. P-values were calculated using one-tailed Student’s t-test. *p<0.05.
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Figure 3. Transcriptional profiling of compounds IXA1, IXA4, and IXA6 shows preferential 
induction of IRE1/XBP1s target genes.
A. Volcano plots from whole-transcriptome RNAseq showing negative log transformed 
adjusted p-values for gene expression (y-axis) versus log2 transformed fold change (x-axis) 
in HEK293T cells treated for 4 hrs with IXA1 (10 μM).
B. Volcano plots from whole-transcriptome RNAseq showing negative log transformed 
adjusted p-values for gene expression (y-axis) versus log2 transformed fold change (x-axis) 
in HEK293T cells treated for 4 hrs with IXA4 (10 μM).
C. Volcano plots from whole-transcriptome RNAseq showing negative log transformed 
adjusted p-values for gene expression (y-axis) versus log2 transformed fold change (x-axis) 
in HEK293T cells treated for 4 hrs with IXA6 (10 μM).
D. Plots showing fold change values from whole-transcriptome RNAseq of target genes 
regulated downstream of the IRE1/XBP1s (red), ATF6 (blue), or PERK (green) signaling 
arms of the UPR expressed as fold change relative to Tg treatment (1 μM, 4hr) in HEK293T 
cells treated with IXA1 (10 μM, 4hr). Center line reflects median, box limits reflect upper 
and lower quartiles, whiskers reflect 1.5x IQ range, and points reflect outliers as calculated 
by Tukey method. The composition of these genesets is shown in Source Data Table 3.
E. Plots showing fold change values from whole-transcriptome RNAseq of target genes 
regulated downstream of the IRE1/XBP1s (red), ATF6 (blue), or PERK (green) signaling 
arms of the UPR expressed as fold change relative to Tg treatment (1 μM, 4hr) in HEK293T 
cells treated with IXA4 (10 μM, 4hr). Center line reflects median, box limits reflect upper 
and lower quartiles, whiskers reflect 1.5x IQ range, and points reflect outliers as calculated 
by Tukey method. The composition of these genesets is shown in Source Data Table 3.
F. Plots showing fold change values from whole-transcriptome RNAseq of target genes 
regulated downstream of the IRE1/XBP1s (red), ATF6 (blue), or PERK (green) signaling 
arms of the UPR expressed as fold change relative to Tg treatment (1 μM, 4hr) in HEK293T 
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cells treated with IXA6 (10 μM, 4hr). Center line reflects median, box limits reflect upper 
and lower quartiles, whiskers reflect 1.5x IQ range, and points reflect outliers as calculated 
by Tukey method. The composition of these genesets is shown in Source Data Table 3.
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Figure 4. Compounds IXA4 and IXA6 show selectivity for IRE1/XBP1s-dependent ER 
proteostasis remodeling.
A. Gene Ontology (GO) analysis of differentially expressed genes from RNAseq for 
HEK293T cells treated with IXA4 (10 μM, 4hr). Top 15 entries with lowest FDR are shown. 
See Supplementary Table 4 for full GO analysis.
B. Gene Ontology (GO) analysis of differentially expressed genes from RNAseq for 
HEK293T cells treated with IXA6 (10 μM, 4hr). Top 15 entries with lowest FDR are shown. 
See Supplementary Table 4 for full GO analysis.
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C. Venn diagram of genes upregulated >1.2 fold (adjusted p-value <0.05) in HEK293T cells 
treated with compound IXA4 (10 μM) for 4 hrs in comparison to genes induced >1.2 fold 
(adjusted p-value < 0.05) in HEK293DAX cells treated with doxycycline (1 μg/mL) for 4 hrs. 
Genes listed in purple are top overlapping targets between conditions.
D. Venn diagram of genes upregulated >1.2 fold (adjusted p-value <0.05) in HEK293T cells 
treated with compound IXA6 (10 μM) for 4 hrs in comparison to genes induced >1.2 fold 
(adjusted p-value < 0.05) in HEK293DAX cells treated with doxycycline (1 μg/mL) for 4 hrs. 
Genes listed in purple are top overlapping targets between conditions.
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Figure 5. Compound IXA4 increases degradation of amyloid precursor protein (APP) mutants.
I. Plot of log2 Fold Change mRNA levels from RNAseq in cells treated with IXA4 (10 μM, 
4hr) of proteostasis factors found in the ER, cytosol/nucleus, or mitochondria. The 
composition of these proteostasis genesets is shown in Source Data Table 3.
J. Graph showing relative signal from ELISA of secreted Aβ peptide in conditioned media 
from CHO7PA2 cells treated with IXA4 (10 μM) in the presence or absence of 4μ8c (32 μM). 
Cells were pretreated for 18 hrs with compounds. Media was then replaced and conditioned 
in the presence of compounds for 24 hrs before harvesting conditioned media for ELISA. 
Secreted Aβ was normalized to that observed in untreated controls. Error bars represent SE 
for n = 3 replicates. P-values calculated from one-tailed Student’s t-test. **p<0.01, 
***p<0.001.
K. Quantification of mutant APP relative to vehicle-treated controls in media and lysate 
isolated from CHO7PA2 cells treated with IXA4 (10 μM) and/or 4μ8c (32 μM) as in panel B, 
measured by immunoblotting. A representative immunoblot is shown in Extended Data Fig. 
8A. Error bars represent SD for n = 3 replicates. P-values calculated from one-tailed 
Student’s t-test. *p<0.05, ***p<0.001.
L. Representative autoradiogram showing the [35S] metabolic labeling of mutant APP in 
CHO7PA2 cells treated with IXA4 (10μM) for 16 hrs prior to 30 min labeling. Media and 
lysates were collected at 0, 1, or 2 hrs and [35S]-labeled mutant APP was isolated by 
immunopurification. The experimental protocol is shown above.
M. Plot showing fraction mutant APP remaining at each time point of the metabolic labeling 
experiment shown in panel D. Fraction remaining was calculated using the following 
equation: (APP in lysate at time = t + APP in media at time = t) / (APP in lysates at t = 0 + 
APP in media at t = 0). Error bars represent SD for n = 3 replicates. P-values were calculated 
from one-tailed Student’s t-test. *p<0.05, **p<0.01.
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N. Plot showing fraction of fraction APP secreted at 2 hrs of the metabolic labeling 
experiment shown in panel D. Fraction secretion was calculated using the following 
equation: (APP in media at time = t) / (APP in lysates at t = 0 + APP in media at t = 0). Error 
bars represent SD for n = 3 replicates. P-values were calculated from one-tailed Student’s t-
test. *p<0.05.
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Figure 6. The IRE1/XBP1s activator IXA4 rescues mitochondrial defects in SH-SY5Y cells 
expressing disease-relevant APP mutants.
D. Representative histograms showing TMRE staining of SHSY5Y cells transiently 
expressing empty vector (Mock), wild-type APP (APPWT), or Swedish mutant APP 
(APPSW).
E. Quantification of TMRE staining from panel A. TMRE normalized to geometric mean 
from cells transiently expressing empty vector (Mock). Error bars represent SD for n = 3 
replicates. P-values were calculated from one-tailed Student’s t-test. *p<0.05, **p<0.01.
Grandjean et al. Page 39













F. Representative histograms showing TMRE staining of SHSY5Y cells transiently 
expressing empty vector (Mock) or APPSW in the presence or absence of IXA4 (10 μM) for 
72 hrs.
G. Quantification of TMRE staining from panel C. TMRE normalized to geometric mean 
from cells transiently expressing empty vector (Mock). Error bars represent SE for n = 3 
replicates. P-values were calculated from one-tailed Student’s t-test. *p<0.05.
H. Graph showing relative ATP levels measured by CellTiterGlo luminescence in SHSY5Y 
cells transiently expressing empty vector or APPSW cultured in either normal high glucose 
media or glucose-free media supplemented with galactose for 72 hrs. Luminescence signal 
was normalized to that observed in cells transiently expressing empty vector (Mock) 
cultured in glucose- or galactose-containing media. Error bars represent SE for n = 3 
replicates. P-values were calculated from one-tailed Student’s t-test. *p<0.05
I. Graph showing relative ATP levels measured by CellTiterGlo luminescence in SHSY5Y 
cells transiently expressing empty vector (Mock) or APPSW cultured in galactose media for 
72 hrs in the presence or absence of IXA4 (10 μM). Luminescence signal was normalized to 
that observed in cells transiently expressing empty vector (Mock) incubated in the absence 
of IXA4. Error bars represent SD for n = 3 replicates. P-values were calculated from one-
tailed Student’s t-test. ***p<0.001.
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